Biofrontera reports preliminary revenue for the month of June 2021
July 06 2021 - 10:00AM
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the
“Company”), an international biopharmaceutical company, today
reported preliminary, unaudited revenue for the month of June 2021.
The Company’s preliminary, unaudited revenue
from product sales in June 2021 amounted to approximately EUR 2,626
thousand, compared to EUR 1,701 thousand in June 2020, an increase
of 50%.
Preliminary revenues from product sales in the
US were around EUR 1,375 thousand compared to EUR 1,235 thousand in
June 2020, an increase of 11%. In Germany, revenues from product
sales amounted to approximately EUR 417 thousand, compared to EUR
370 thousand in June 2020, an increase of 12%. In the rest of
Europe, the Company generated product sales of around EUR 834
thousand, compared to EUR 96 thousand in June 2020, a plus of 770%.
Sales in June this year include the first batch of Ameluz® for
reintroduction in the Scandinavian market by Galenica AB.
Preliminary unaudited
revenues
|
June |
Q2 |
in EUR thousands |
2021 |
2020 |
2019 |
2021 |
2020 |
2019 |
USA |
1,375 |
1,235 |
1,539 |
4,861 |
2,166 |
5,060 |
Germany |
417 |
370 |
309 |
1,285 |
1,054 |
1,081 |
Europe (ex Germany) |
834 |
96 |
361 |
1,448 |
146 |
793 |
Total revenue from product sales |
2,626 |
1,701 |
2,199 |
7,595 |
3,366 |
6,934 |
Revenues from R&D projects and license payments |
0 |
48 |
54 |
0 |
6,278 |
162 |
Total revenue |
2,626 |
1,750 |
2,253 |
7,595 |
9,644 |
7,096 |
Due to commercial rounding, rounding differences
may occur in tables.
Due to the pandemic, the monthly and quarterly
sales development is compared with sales in 2019 for increased
transparency. As such, an increase of 19% in June 2021 total
product sales was achieved in all markets compared to June 2019. In
more detail, June 2021 sales were up by 35% in Germany and by 131%
in the remaining European markets compared to June 2019. In the
USA, product sales decreased by 10%. The decline was mainly caused
by no or lower sales of Aktipak® and Xepi®, respectively, while
sales of Ameluz® were at a comparable level.
In Q2 2021, product sales in all markets were up
by around 10% compared to Q2 2019. Sales in Q2 2021 increased by
around 19% in Germany and by almost 83% in the rest of the European
market compared to Q2 2019. Revenue in the US market was down 4%,
mainly due to the lack of or lower sales of Aktipak® and Xepi®,
while sales of Ameluz® showed a slight increase compared to Q2
2019.-End-
Biofrontera AGPamela Keck, Head of Investor
Relationsir@biofrontera.com+49-214-87632-0
About Biofrontera: Biofrontera
AG is a biopharmaceutical company specializing in the development
and sale of dermatological drugs and medical cosmetics.
The Germany-based company, with over 150
employees worldwide, develops and markets innovative products for
the care, protection and treatment of the skin. The company’s lead
product is the combination of Ameluz®, a topical prescription drug,
and medical device BF-RhodoLED® for the photodynamic therapy of
certain superficial skin cancers and their precursors. Ameluz® has
been marketed in the EU since 2012 and in the United States since
May 2016. In addition, the company markets the prescription
medication Xepi® for the treatment of impetigo in the United
States. In the EU, the company also sells the dermocosmetics series
Belixos®, which offers specialized care for damaged or diseased
skin.
Biofrontera is the first German founder-led
pharmaceutical company to receive a centralized European and a US
approval for a drug developed in-house. The Biofrontera Group was
founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is
listed on the Frankfurt Stock Exchange (Prime Standard) and on the
US NASDAQ.www.biofrontera.com.
Forward-Looking Statements: Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995 regarding the
public offering and the intended use of proceeds from the
offering.
These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimate" and "intend," among others. Such forward-looking
statements are based on the currently held beliefs and assumptions
of the management of Biofrontera AG, which are expressed in good
faith and, in their opinion, reasonable. Forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition,
performance, or achievements of the Company, or industry results,
to differ materially from the results, financial condition,
performance or achievements expressed or implied by such
forward-looking statements. These risks, uncertainties and other
factors are set forth in the annual report on Form 20-F filed with
the SEC, including Item 3.D. "Key Information - Risk Factors," and
in future reports filed with the SEC. Given these risks,
uncertainties and other factors, prospective investors are
cautioned not to place undue reliance on these forward-looking
statements. The Company does not undertake an obligation to update
or revise any forward-looking statement.
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Jul 2023 to Jul 2024